Colorectal Cancer Clinical Trials

• Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setting.

• Participants must have received and progressed on no more than 2 previous systemic treatment regimens in the metastatic setting

• Eastern Cooperative Oncology Group (ECOG) performance status less than equal to 1

• Participants must be able to swallow oral tablets, and to comply with the study requirements for all scheduled evaluations

• Other protocol defined inclusion criteria may apply